---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-029591"
form_type: "8-K"
ticker: "RCUS"
cik: "0001724521"
company_name: "Arcus Biosciences, Inc."
filed_at: "2025-02-19T23:59:59+00:00"
generated_at: "2026-05-26T12:17:54.342913+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Arcus Biosciences raises ~$141.6M in public offering of 13.6M shares at $11.00/share

## Summary
- Offered 13,636,364 shares at $11.00/share, yielding ~$141.6M net proceeds after expenses.
- Proceeds to fund R&D activities, including clinical development of casdatifan, manufacturing, and general corporate purposes.
- Offering closed on Feb 19, 2025; underwritten by Goldman Sachs and Leerink Partners.
- Shares sold under existing shelf registration statement (Form S-3) filed with the SEC.

## SEC filing metadata
- accession: 0001193125-25-029591
- form_type: 8-K
- ticker: RCUS
- cik: 0001724521
- company_name: Arcus Biosciences, Inc.
- filed_at: 2025-02-19T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1724521/000119312525029591/0001193125-25-029591-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1724521/000119312525029591/d932072d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-029591
- JSON: https://secwatch.observer/filing/0001193125-25-029591.json
- Plain text: https://secwatch.observer/filing/0001193125-25-029591.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.